Michele Sartori, MD
Interventional Cardiology · Houston, TXNPI 1720078181
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $204,414 of the $266,124 with a category attached, or 76.8%. 57 manufacturers reported payments, led by Novo Nordisk at 59.7% of the total. 2025 is the largest year on record at $68,008, 2.8 times the $24,377 reported in 2019. Among interventional cardiology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 878 payments — averaging $303.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$159K
- Esperion Therapeutics, Inc.$55K
- Abbott$19K
- Sanofi-aventis U.S. LLC$13K
- Regeneron Healthcare Solutions, Inc.$5K
- Abiomed$2K
- plus $14K from 51 others
Across 36 payments — averaging $9365.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$312K
- Novartis$25K
What the payments were for
- Consulting fees$4,6412%
- Speaking & faculty fees$204,41477%
- Travel & lodging$23,0929%
- Food & beverage$33,66713%
- Education$3100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$76,840
- NEXLIZET$53,722
- NEXLETOL$53,722
- PRALUENT$11,199
- DISEASE STATE$3,925
- Quadra Assura CRT Defibrillator$2,550
- XIENCE SKYPOINT$1,905
- GALLANT$1,825
- AMPLATZER AMULET$1,740
- AVEIR$1,730
- MULTAQ$1,500
- Xience V coronary stent system$1,144
- Impella$703
- Xience Sierra Coronary Stent$678
- Fortify Assura$530
- QUADRA ASSURA$513
- FARXIGA$502
- Fortify Assura, Ellipse ICD$492
- Omnilink Elite vascular stent system$376
- Accent Pacemaker$329
How this compares
$266,124 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 269 | $320,634 |
| OpsumitMacitentan | 16 | $212,915 |
| LetairisAmbrisentan | 11 | $142,832 |
| Repatha SureclickEvolocumab | 112 | $125,622 |
| OzempicSemaglutide | 81 | $105,418 |
| JardianceEmpagliflozin | 81 | $101,896 |
| XareltoRivaroxaban | 79 | $79,317 |
| EntrestoSacubitril/Valsartan | 52 | $60,640 |
| AdcircaTadalafil | 11 | $45,947 |
| Praluent PenAlirocumab | 51 | $44,535 |
| FarxigaDapagliflozin Propanediol | 41 | $41,981 |
| MounjaroTirzepatide | 20 | $32,221 |
| NexlizetBempedoic Acid/Ezetimibe | 16 | $15,352 |
| LivaloPitavastatin Calcium | 16 | $12,055 |
| VascepaIcosapent Ethyl | 11 | $11,409 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $174 | $320,634269 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $641 | $212,91516 claims |
| Novo NordiskOzempic | $158,980 | $105,41881 claims |
| Boehringer IngelheimJardiance | $620 | $101,89681 claims |
| Johnson & JohnsonXarelto | $1,252 | $79,31779 claims |
| NovartisEntresto | $577 | $60,64052 claims |
| United Therapeutics CorporationAdcirca | $258 | $45,94711 claims |
| AstraZenecaFarxiga | $1,072 | $41,98141 claims |
| Lilly USA, LLCMounjaro | $22 | $32,22120 claims |
| Esperion Therapeutics, Inc.Nexlizet | $54,947 | $15,35216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Houston
- Juan GranadaHouston$4.1M
- John IsaacHouston$1.8M
- Sanjay KunapuliHouston$267K
- Abhijeet DhobleHouston$161K
- Amir KashaniHouston$148K
- Dhaval ParekhHouston$137K
- Neal KleimanHouston$118K
- Mehran MassumiHouston$114K
- Eduardo HernandezHouston$112K
- Salman ArainHouston$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.